| In partnership with |  |
| Good day, 360! | President Donald Trump is promising us that "The golden age of America begins right now" and that "America's decline is over." No matter what side of the political fence you are on, for America's sake… let's hope he's right! | As for today… please join us for THIS special event: | | | FOCUS LIST🔎 | HSDT - Up over 40% in the pre-market after announcing strong enrollment of its stroke pivotal study exceeding initial target | TEM - Up over 17% in pre after Nancy Pelosi reported purchase of 50 Jan 2026 $20 Call options In Tempus AI on January 14 | VATE - Up over 24% in pre after announcing its MediBeacon® Transdermal GFR System receives FDA approval to assess kidney function | | *sponsored by Klondike Royalties | Add a piece of the energy sector to your portfolio. | | Access to 300 million barrels of recoverable oil reserves Royalty-based investment model reducing operational risks Projected 25+ years of potential royalty income
| Join the Raise |
|
| | HOTLIST🔥 | HSDT - Up over 40% in the pre-market after announcing strong enrollment of its stroke pivotal study exceeding initial target | Helius Medical Technologies Inc. (HSDT) is a a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits. | In the pre-market this morning, the company announced it has completed and far exceeded the initial target enrollment for its stroke registrational program. With 128 participants randomized to-date the program is on track to reach the maximum enrollment target of 150 participants by the end of January 2025. | The stroke registrational program is intended to demonstrate the safety and effectiveness of the novel Portable Neuromodulation Stimulator (PoNS®) for improving balance and gait deficits in stroke survivors. | Shares of HSDT traded up over 40% in the pre-market in reaction to the news. | | The $1.09 area acted as support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $1.24, $1.30 and then the pre-market high at $1.39. Beyond that, $1.45, $1.50, $1.70 and $2 come into play. | Below $1.09, targets to the downside are $1, $0.90, $0.85 and then a gap fill at $0.7510. | | TEM - Up over 17% in pre after Nancy Pelosi reported purchase of 50 Jan 2026 $20 Call options In Tempus AI on January 14 | Tempus AI Inc (TEM) operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. | Earlier this morning it was disclosed that former House Speaker Nancy Pelosi reported the purchase of 50 Jan 2026 $20 Call options In Tempus AI on January 14. Having shown a phenomenal track record between herself and her husband in recent years in investments, the disclosure sent shares of TEM trading up over 17% in the pre-market. | | The $41.39 area acted as support in the pre-market and now becomes a potential level of resistance. | Above it, targets to the upside are $42, $43, $44.50 and then the pre-market high at $45.25. Beyond that, $47 and $51 come into play. | Below $41.39, targets to the downside are $40.59, $38.50, $37.50, $36 and then a gap fill at $35.15. | | VATE - Up over 24% in pre after announcing its MediBeacon® Transdermal GFR System receives FDA approval to assess kidney function | INNOVATE Corp. (VATE) through its subsidiaries, operates in infrastructure, life sciences, and spectrum areas in the United States. | In the after-hours Friday, the company announced that the U.S. Food and Drug Administration (FDA) has approved the MediBeacon® TGFR for the assessment of kidney function in patients with normal or impaired renal function. | Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function | The transdermal GFR (tGFR) methodology has been designed to be effective across the adult population without input of age, weight, sex, gender, race, or ethnicity | More than 800 million people have Chronic Kidney Disease (CKD), one of the world's leading causes of mortality worldwide, with associated deaths increasing over the past two decades | Shares of VATE traded up over 24% in the pre-market in reaction to the news. | | The $7.20 area acted as support in the pre-market and now becomes a potential level of resistance. | Above it, targets to the upside are $8, $8.20, $8.40 and then the pre-market high at $8.91. Beyond that, $9.56 and $10 come into play. | Below $7.20, targets to the downside are $6, $5.70 and then a gap fill at $5.11. | | MARKET NEWS 📰 | | | Don't miss out on our MOBILE ALERTS! Some of these alerts have rocketed 🚀past the MOON 🌝. Text "RAGE" to 1-(888) 487-1534 📲. | | DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at https://ragingbull.com/disclaimer | FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. | RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. | RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. | RagingBull.com, LLC shall be entitled to recover attorneys' fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys' fees, costs and disbursements in addition to any other relief to which it may be entitled. | *Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don't spend any money on these products or services unless you believe they will help you achieve your goals. | WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. |
|
|
|
Tidak ada komentar:
Posting Komentar